Conference Coverage

End-of-life aggressive cancer care continues despite recommendations


 

AT THE 2016 ASCO ANNUAL MEETING

References

Limitations of the study include a lack of information on the cause of death (whether related to the cancer, the treatment received, or other), and researchers did not review the medical records to investigate the medical reasons for the use of aggressive care near the end of life.

Pages

Recommended Reading

Advances in the management of multiple myeloma
MDedge Hematology and Oncology
Exercise linked to fewer cardiovascular events in nonmetastatic breast cancer patients
MDedge Hematology and Oncology
Materials help families find support for children with serious illnesses
MDedge Hematology and Oncology
Effects of exercise interventions during different treatments in breast cancer
MDedge Hematology and Oncology
Omission of dexamethasone from antiemetic treatment for highly emetogenic chemotherapy in breast cancer patients with hepatitis B infection or diabetes mellitus
MDedge Hematology and Oncology
Culture-broker and medical decoder: contributions of caregivers in American Indian cancer trajectories
MDedge Hematology and Oncology
Paraneoplastic syndrome and underlying breast cancer: a worsening rash despite initiation of chemotherapy
MDedge Hematology and Oncology
Targeting vagal activity could improve breast cancer survival
MDedge Hematology and Oncology
A new sort of consultant: Advising doctors, patients on California’s aid-in-dying law
MDedge Hematology and Oncology
Cancer drugs most affordable in Australia, least in India and China
MDedge Hematology and Oncology